Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tasly Group Halts Trading After Adverse Report On Its Cardiotonic Pill

This article was originally published in PharmAsia News

Executive Summary

An academic fingered for falsifying his research paper has turned the table on the accuser after Zhejiang University found the real author to be a protégé. Li Lianda, the implicated academic, claimed the allegation was made by an advisor of Tasly Group after Li announced his research on the severe side effects caused by the firm's Cardiotonic Pill. The company asked him not to publish the results but he went ahead, thus he suspected the false paper "exposé" was linked to the incident. Upon media reporting of Li's statement, Tasly Group's share dropped 3.8 percent, leading to an urgent halt in trading. The firm issued a statement that the advisor's accusation was made in his personal capacity and denied any association. It emphasized that the drug has received China State FDA approval after thousands of clinical trials. (Click here for more - Chinese Language)

You may also be interested in...



China’s State FDA Responds To Cardiotonic Pill Incident

China's State FDA has made an official response to the report on Cardiotonic Pill side effects (PharmAsia News, Feb. 9, 2009). Zhang Wei, director general of SFDA's Department of Drug Registration, stated that Cardiotonic Pill is registered as a modified dosage form of Salvia miltiorrhiza tablet. Both the dosage change for the generic drug and the brand drug have been studied by designated research institutes according to the requirements of the registration application. Cardiotonic Pill registration review shows that toxicity testing has been conducted in various phases over different periods, especially since the drug has applied for R&D experiments in the U.S. SFDA said that public release of the National Center for ADR Monitoring will be the most authoritative evaluation for adverse drug reactions. (Click here for more - Chinese language)

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

UsernamePublicRestriction

Register

SC070990

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel